Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07362875 · ClinicalTrials.gov registry record
Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
A clinical trial of Myotonic Dystrophy, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT07362875 is a study of Myotonic Dystrophy that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 75 participants, below the 847-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07362875, a study of Myotonic Dystrophy, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
Myotonic dystrophy (dystrophia myotonica; DM), the most prevalent form of muscular dystrophy in adults, is characterized by progressive myopathy, myotonia, and multi-systemic involvement. DM causes severe disability and profoundly affects the patient's quality of life. Currently, no effective treatments are available that alter the course of the disease, but ongoing clinical trials are underway.
Conditions Studied
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2029-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07362875
The ClinicalTrials.gov registry entry for NCT07362875 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 847-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (91% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myotonic Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT07362875 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT07362875 about?
NCT07362875 is a clinical study titled "Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy". Myotonic dystrophy (dystrophia myotonica; DM), the most prevalent form of muscular dystrophy in adults, is characterized by progressive myopathy, myotonia, and multi-systemic involvement. DM causes severe disability and profoundly affects the patient's quality of life. Currently, no effective treatm...
What is the current status of trial NCT07362875?
This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2025-05-15. Estimated completion is 2029-05.
What conditions does trial NCT07362875 study?
This clinical trial studies the following conditions: Myotonic Dystrophy.
Who is sponsoring clinical trial NCT07362875?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07362875 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myotonic Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1
RECRUITING · Phase 1
-
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
RECRUITING
-
Extracellular RNA Biomarkers of Myotonic Dystrophy
RECRUITING
-
Myotonic Dystrophy Family Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.